Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02750280 · ClinicalTrials.gov registry record · NA
A Longitudinal Study to Evaluate an Extracellular Matrix (MatriStem®) for the Treatment of Diabetic Foot Ulcers
A NA study of Neuropathic Diabetic Foot Ulcer, sponsored by Calvary Hospital, Bronx, NY.
- Completed
- Registry status
- NA
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT02750280: Completed NA study of Neuropathic Diabetic Foot Ulcer, sponsored by Calvary Hospital, Bronx, NY.
NCT02750280 is a NA study of Neuropathic Diabetic Foot Ulcer that has completed, run by Calvary Hospital, Bronx, NY. The registered enrollment target is 17 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02750280, a NA study of Neuropathic Diabetic Foot Ulcer, has completed, sponsored by Calvary Hospital, Bronx, NY.
- COMPLETED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
This ia a prospective controlled longitudinal study to evaluate the effects of MatriStem® plus standard local wound care versus standard local wound care alone in the treatment of diabetic foot ulcers (DFUs), as assessed by incidence of complete wound healing by 16 weeks and ulcer recurrence with a 2 year follow-up.
Conditions Studied
Interventions
- DEVICE MatriStem® [Urinary Bladder Matrix (UBM)]
- DEVICE Mepilex® [Silicone foam dressing]
Study Locations (1)
New York
- Calvary Hospital Center for Curative and Palliative Wound Care - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-12 |
| Phase | NA |
What the finished NCT02750280 record still lists
NCT02750280 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Neuropathic Diabetic Foot Ulcer appearing as the primary indexed condition, and to 2 interventions - of which MatriStem® [Urinary Bladder Matrix (UBM)] is the first listed.
NCT02750280 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02750280 about?
NCT02750280 is a clinical study titled "A Longitudinal Study to Evaluate an Extracellular Matrix (MatriStem®) for the Treatment of Diabetic Foot Ulcers". This ia a prospective controlled longitudinal study to evaluate the effects of MatriStem® plus standard local wound care versus standard local wound care alone in the treatment of diabetic foot ulcers (DFUs), as assessed by incidence of complete wound healing by 16 weeks and ulcer recurrence with a ...
What is the current status of trial NCT02750280?
This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2015-06. Estimated completion is 2015-12.
What conditions does trial NCT02750280 study?
This clinical trial studies the following conditions: Neuropathic Diabetic Foot Ulcer.
What interventions are being tested in trial NCT02750280?
The interventions under investigation include: MatriStem® [Urinary Bladder Matrix (UBM)] (DEVICE), Mepilex® [Silicone foam dressing] (DEVICE).
Who is sponsoring clinical trial NCT02750280?
This trial is sponsored by Calvary Hospital, Bronx, NY, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02750280 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02750280's enrollment target sits among peer trials
17 1871st of 2000 higher than 130 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia